Mikhail Blagosklonny is a great Oncologist who is revered for his relentless efforts in the cancer research field. Mikhail background training places him at a good place to tackle his roles meticulously. He is a Ph.D. holder in experimental medicine and cardiology, earned from the First Pavlov State Medical University of St. Petersburg the same institute that he got his M.D in internal medicine.
Mikhail’s first role was in 2002 at the New York Medical College strategically positioned in Valhalla, New York where he worked as an Associate Professor. He then undertook a position at the Ordway Research Institute as a Senior Scientist before an Oncology Professor role beckoned at the Roswell Park Cancer Institute in 2009. His expertise over the years has shaped him to be the great professor that he is currently.
Besides his normal work, Mikhail Blagosklonny has written many articles about medical research, such as the hyperfunction theory, cell cyclotherapy, and chemotherapeutic engineering among others. He has written 300 unique and well-formatted research articles, reviews, and books contribution published in his name. Mikhail Blagosklonny holds the role of the Chief Editor for Oncotarget and Cell cycle as well as an associate editor for PLOS ONE, cancer biology, and therapy, the American Journal of Pathology, and International Journal of Cancer. He is also an official member and key decision-maker of the editorial board for Cell Death and Differentiation.
Involvement in Cancer Research
Mikhail’s interest in cancer research is driven by his love for humanity and the desire to see the world being free of cancer. His efforts run deep and wide in this sector starting with his research in Biogerontology that studies about protecting healthy cells from damage through the use of anti-aging drugs and therapies. In one of his research, Mikhail Blagosklonny came up with a theory that shows the role that Tor Signaling plays in aging and cancer. He suggested the use of a cancer drug named rapamycin in treatment and possibly prolonging life. His other research varies from clinical to cellular and molecular biologies, such as oncogenesis, tumor suppressors, apoptosis, cell cycle, anticancer therapeutics, mitosis, signal transduction, and drug resistance for normal cells. Visit ResearchGate.Net to learn more about Mikhail’s latest work.